Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

@article{Singh2008InhaledAA,
  title={Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.},
  author={Sonal Singh and Y. Loke and C. Furberg},
  journal={JAMA},
  year={2008},
  volume={300 12},
  pages={
          1439-50
        }
}
  • Sonal Singh, Y. Loke, C. Furberg
  • Published 2008
  • Medicine, Materials Science
  • JAMA
  • CONTEXT Inhaled anticholinergics (ipratropium bromide or tiotropium bromide) are widely used in patients with chronic obstructive pulmonary disease (COPD) but their effect on the risk of cardiovascular outcomes is unknown. OBJECTIVE To ascertain the cardiovascular risks of inhaled anticholinergics, including cardiovascular death, myocardial infarction (MI), and stroke. DATA SOURCES Systematic searches were conducted on March 19, 2008, of relevant articles in MEDLINE, the Cochrane Database… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    The purpose of this study is to evaluate the use of spirometry in identifying Diagnostic Error in COPD and Asthma patients.  
    ConditionsCOPD Asthma
    InterventionDevice, Drug
    INTERVENTIONAL CLINICAL TRIAL
    Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory (lung) disease that makes it harder to breathe over time. To date, there is no cure for COPD, but it can be… Expand
    ConditionsChronic Obstructive Pulmonary Disease
    InterventionDevice, Drug
    A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD
    34
    Do Inhaled Anticholinergics Increase or Decrease the Risk of Major Cardiovascular Events?
    25

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 65 REFERENCES